SCHEMBL23970975

SCHEMBL23970975

C=C(C)c1ccc2ccn(S(=O)(=O)c3ccccc3)c2n1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.55
HTR6 P50406 12/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
PKM P14618 2/20 0.42
POLB P06746 1/20 0.41
DRD2 P14416 2/20 0.40
HTR1A P08908 1/20 0.40
FGFR4 P22455 1/20 0.40
BRD4 O60885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29187957 0.88 CYP2C19 (0.56) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL18370167 0.79 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL23620190 0.79 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL29641246 0.78 CYP2C19 (0.45) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL24568042 0.78 CYP2C19 (0.45) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL21188439 0.77 CYP2C19 (0.47) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL2009025 0.76 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL2007654 0.76 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL2011040 0.76 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AALDH1A1
SCHEMBL30411274 0.76 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 CN disclosed
EP-4267562-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2023-11-01 EP disclosed
EP-4143189-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2023-03-08 EP disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
WO-2022140390-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 CYP2C19 4410/4885HTR6 3644/4885MEN1 2517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.